Your search found 3 Results
Geneva, Switzerland, World Health Organization [WHO], Stop TB Department, 2003.  p. (WHO/CDS/TB/2003.319; WHO/HIV/2003.01)The main aim of the guidelines is to enable the central units of national TB and HIV/AIDS programmes to support districts to plan, coordinate and implement collaborative TB/HIV activities. The guidelines are intended for countries with either an overlapping TB and HIV epidemic or where there is an increasing HIV rate which may fuel the TB epidemic. The WHO “Strategic Framework to Reduce the Burden of TB/HIV" provides the evidence base for these guidelines. The guidelines are designed to implement the interventions as described in this framework. The guidelines reflect lessons learned from TB/HIV field sites including ProTEST with experience from comprehensive TB/HIV health services and interventions. The guidelines are structured in line with the main theme of putting these interventions into action: what to implement, how to implement it and by whom. The health situation is urgent and requires a move away from small scale, often costly and time-limited pilot projects to phased implementation of collaborative TB/HIV activities. Phased implementation will build on experience learned form ProTEST pilot sites. Human and financial constraints make phased implementation necessary. (excerpt)
Promoting behavior change in Botswana: an assessment of the Peer Education HIV / AIDS Prevention Program at the workplace.
Journal of Health Communication. 2003 May-Jun; 8(3):267-281.Botswana has the highest rate of HIV prevalence in the world and AIDS has now reached crisis proportions in the country. Among the initiatives implemented as a response, to promote sexual behavior change, is the Peer Education HIV/AIDS Prevention Program (PEHAPP) at the workplace. This paper assesses the impact and outcome of the PEHAPP. It concludes that the PEHAPP is having a measurable positive impact in the key areas of improving knowledge, attitudes, and practices related to risky sexual behavior which, in turn, should reduce the incidence of transmission of HIV/AIDS and other STDs over the long-term. (author's)
WORLD HEALTH ORGANIZATION TECHNICAL REPORT SERIES.. 1998; (874):v-vi, 1-43.This book provides an update on the global leprosy situation emphasizing the availability of technology for disease elimination, identification of obstacles, and development of appropriate recommendations for leprosy prevention. Section 1 presents the actions undertaken by the WHO in response to the increasing incidence of leprosy worldwide. Section 2 discusses the current status of leprosy through a presentation of estimated, registered and detected cases, as well as the success of multidrug therapy in disease elimination. Section 3 presents the definition, diagnosis, clinical manifestations, and other epidemiologic conditions affecting the disease. Section 4 reviews the current available drugs, which include dapsone, rifampicin, clofazimine, ofloxacin, minocycline, clarithromycin and their adverse reactions. Section 5 discusses management of reactions and neuritis, while section 6 presents the disabilities and rehabilitation associated with the disease. The rest of the chapters present a global strategy on leprosy elimination, monitoring, antiepilepsy activity integration, community action and participation, and research priorities. Based on the field trial and clinical study results, the Committee confirms the cost-efficacy and acceptability of a single dose combination of rifampicin, ofloxacin and minocycline as an alternative regimen. In conclusion, the need for improved reaction and neuritis management, prevention of leprosy-related disabilities and impairments and implementation of antileprosy activities as an integral part of the health services is highlighted.